We investigated whether a causal relationship exists between human herpesvirus 6 (HHV-6) and skin rash resembling acute graft-versus-host disease (GVHD) following bone marrow transplantation (BMT). Isolation of HHV-6 was used to monitor active HHV-6 infection in this study. We analyzed 25 episodes of skin rash in 22 recipients. All recipients were seropositive for HHV-6 before BMT. The onset of skin rash started prior to 30 days post transplantation (group A) in 15 of 25 cases, but after that (group B) in the remaining 10 cases. Twenty-five skin tissue samples were obtained from 22 recipients. The HHV-6 genome was detected in four of 15 skin samples from group A, but not detected in those from group B. HHV-6 was isolated from 11 of 22 recipients around 2 to 3 weeks after BMT (range 14 to 28 days after BMT). HHV-6 was isolated at a time between 10 days before and after the onset of skin rash (skin rash-related viremia) in nine cases in group A. Meanwhile, no skin rash-related viremia was observed in group B. Of the four recipients with positive detection of HHV-6 genome in their skin tissue (group A), two had HHV-6 viremia at the same time. The association between the timing of HHV-6 infection and the onset of skin rash was analyzed statistically. HHV-6 viremia (skin rash-related viremia) was found in nine of 15 (60%) cases in group A, compared with none of 10 (0%) cases in group B. This difference was statistically significant (P = 0.008). Moreover, HHV-6 infection (skin rash-related viremia and/or positive detection of HHV-6 DNA in skin tissue) was demonstrated in 11 of 15 (73.3%) cases in group A, compared with none of 10 (0%) cases in group B (P = 0.001). Thus, this study suggests that HHV-6 may be involved in the development of skin rash in the first month after allogeneic BMT. Bone Marrow Transplantation (2001) 28, 77-81.
Human herpesvirus 6 (HHV-6) is a recently discovered member of the human herpesvirus family. 1 Although primary infection with variant B HHV-6 causes exanthem subitum, 2,3 the clinical features of variant A HHV-6 infection remain unclear. The virus probably latently infects the body after primary infection and then reactivates in an immunosuppressed host as do other human herpesviruses. HHV-6 has recently been recognized as an opportunistic pathogen in transplant recipients. It has been demonstrated that HHV-6 is associated with fever and skin rash resembling acute graft-versus-host disease (GVHD), [4] [5] [6] [7] [8] [9] [10] interstitial pneumonitis, 11, 12 encephalitis, 13 and bone marrow suppression 14 after bone marrow transplantation (BMT). Despite improvements in immunosuppressive treatments, GVHD remains a serious complication of allogeneic BMT. Viruses can possibly trigger or enhance acute GVHD by changing the expression of surface molecules relating to histocompatibility and cell adhesion. Conversely, viral infections can also be increased due to acute GVHD or its treatment. We reported an association between HHV-6 infection and skin rash resembling acute GVHD in 1991. 4, 5 Although several investigators have studied the causal relationship between the virus infection and acute GVHD or skin rash, the contribution of HHV-6 to the symptoms is still unclear. Some studies have demonstrated that HHV-6 is a risk factor in causing acute GVHD, 4-10 and others did not support a positive association between HHV-6 and acute GVHD. 15, 16 To clarify the issue, two institutes have attempted to detect the virus genome in skin tissues obtained from recipients, 7, 8 and have suggested that HHV-6 plays an important role in the development of acute GVHD or skin rash after allogeneic BMT. Most of the previous studies in terms of HHV-6 infection after BMT employed polymerase chain reaction (PCR) analysis to monitor virus activity. 15 However, as it has been suggested that HHV-6 latently infects monocytes/macrophages after primary infection, 17 use of PCR to detect virus genome in peripheral blood mononuclear cells (PBMC) runs the risk of detecting latent virus (false positive).
To determine whether HHV-6 is associated with the occurrence of acute GVHD or skin rash after allogeneic BMT, we retrospectively analyzed skin tissues for the presence of the virus genome and employed virus isolation from PBMC to identify active virus infection. Moreover, another important point in the elucidation of the causal relationship between the virus infection and clinical features in these patients is the correlation between the timing of these events. A temporal correlation between virus infection and onset of skin rash was considered to determine a causal relationship between the two events in present study.
Patients and methods

Characteristics of patients
Twenty-two patients received an allogeneic BMT in the Division of Hematology-Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, the Department of Pediatrics, Nagoya University School of Medicine, and the Department of Internal Medicine, Fujita Health University School of Medicine. All patients or the guardians of the patients consented to be in this study. Patient characteristics relating to age, sex, underlying disease, and recipient's HHV-6 antibody titers at the time of BMT are summarized in Table 1 . Median age of the recipi- d HHV-6 was isolated 10 days before or after the onset of skin rash. ML = malignant lymphoma; ALL = acute lymphoblastic leukemia; AML = acute myelogeneous leukemia; CML = chronic myelogeneous leukemia; AA = aplastic anemia; WAS = Wiskott Aldrich syndrome. ents was 19.5 years old (ranging from 1 to 57 years old) at the time of BMT. We analyzed 25 episodes of skin rash (indicated as case) in 22 recipients in this study.
Management of patients
Details of conditioning regimens and GVHD prophylaxis are described elsewhere. 18, 19 In brief, patients with hematological malignancies were conditioned with melphalan (180 mg/m 2 ) plus busulfan (16 mg/kg) or total body irradiation (12 Gy) with high-dose chemotherapy. Patients with severe aplastic anemia were conditioned with cyclophosphamide (50 mg/kg) and ATG (lymphoglobulin, 15 mg/kg). GVHD prophylaxis consisted of MTX with or without cyclosporine. Patients received intravenous ␥-globulin preparations weekly during the first 3 months as prophylaxis for cytomegalovirus infection. Oral acyclovir at a dose of 300 to 1000 mg was given daily.
Sample preparation
EDTA-treated peripheral blood was collected biweekly from recipients until 2 months after BMT. Skin biopsy samples were obtained whenever GVHD was clinically suspected (between 0 and 11 days after the onset of skin rash, mean Ϯ s.d.; 3.4 Ϯ 2.4 days), and EDTA-treated peripheral blood was collected at the same time. Skin biopsy specimens were stored at −80°C until DNA extraction.
Isolation and identification of HHV-6
Procedures for isolation and identification of HHV-6 have been described elsewhere. 2 Briefly, peripheral blood mononuclear cells were cocultured with cord blood mononuclear cells in culture medium. Virus isolation was considered positive if the following were present: (1) large cell formation of cultured cells and (2) specific immunofluorescence staining with monoclonal antibodies to HHV-6 (kindly provided by Dr T Okuno, Department of Microbiology, Hyogo College of Medicine, Hyogo, Japan).
Serological assay to detect HHV-6 antibodies
Antibody titers to HHV-6 were measured by an indirectimmunofluorescence assay as described previously. 20 The representative strain of HHV-6 variant B (FG-1), isolated from PBMCs obtained from an exanthem subitum patient was used as the standard antigen. The antibody titer was defined as the reciprocal of the serum dilution showing specific fluorescence.
Extraction and amplification of HHV-6 DNA from skin tissues
Biopsy specimens were incubated overnight in lysis buffer (10 mm Tris HCl, pH 8.0, 150 mm NaCl, 1 mm EDTA, 0.4% sodium dodecyl sulfate, 1 mg/ml proteinase K) at 65°C. DNA was extracted by phenol-chloroform treatment followed by ethanol precipitation. Five hundred ng of total DNA (quantified spectrophotometrically) was used for the PCR. Nested PCR for HHV-6 DNA used two primer sets (A/C, HS6AE/HS6AF) as described previously. 21 Reactions contained of 50 m KCl, 10 mm Tris (pH 8.3), 1.5 mm MgCl 2 , 200 m deoxynucleotide triphosphates (dATP, dCTP, dGTP, and dTTP), 0.5 mm of each primer, and 2.5 U of Taq DNA polymerase (Ampli Taq Gold; Perkin-Elmer, Norwalk, CT, USA). A Perkin-Elmer Cetus model 9600 DNA thermocycler was programmed as follows: 10 min at 95°C; 30 cycles of 1 min at 94°C, 1 min at 57°C, and 1 min at 72°C; and 10 min at 72°C. Samples were held at 4°C until the products could be analyzed. Aliquots of TE buffer were processed as a negative control, and appropriate precautions were taken during sample preparation and performance of the PCR to avoid cross contamination. Moreover, all specimens were analyzed using a primer to the ␤-globin gene to confirm the absence of residual PCR inhibitors in the sample. PCR resulted in the amplification of a 751 base pair DNA fragment encoding a putative large tegument protein gene.
Statistical analysis
The chi-square test was used to analyze an association between active HHV-6 infection and the onset of skin rash.
Results
The results of serological assay, virus isolation, and PCR in skin tissues are shown in Table 1 . All recipients were Bone Marrow Transplantation seropositive to HHV-6 before BMT. Twenty-five skin tissue samples were obtained from 22 recipients. As we reported previously, all HHV-6 was isolated between 14 and 28 days after BMT. This result indicates that active viral infection occurs in the early time period post transplantation. We therefore evaluated the relationship between the virus infection and skin rash in two divided groups according to the onset of skin rash. Skin rashes appeared before 30 days post transplantation (group A) in 15 of the 25 cases, and started after that time (group B) in the remaining 10 cases. HHV-6 genome was detected in four of 15 skin samples in group A. However, it was not detected in the skin samples in group B. HHV-6 was isolated from 11 of 22 recipients around 2 to 3 weeks after BMT (range 14 to 28 days after BMT).
In order to determine if an association between HHV-6 infection and skin rash exists, we examined whether the virus was isolated 10 days before or after the onset of skin rash. Isolation of virus during that period was taken to indicate that viremia was associated with the onset of skin rash (skin rash-related viremia). Skin rash-related HHV-6 viremia was observed in nine cases (cases 5, 6, 7, 8, 9, 10, 11, 14 and 15) in group A (Table 1) .
Of the four cases with HHV-6 genome detected in skin tissue, two cases (cases 14 and 15) also had HHV-6 viremia at the same time, whereas the remainder (cases 12 and 13) did not have viremia. There were seven cases (cases 5, 6, 7, 8, 9, 10 and 11) with skin rash-related HHV-6 viremia, but in whom the virus genome was not detected in the skin tissues.
Since it is of interest to determine if there is an association between the onset of skin rash and HHV-6 infection, we sought an association between the timing of skin rash and viral infection ( Table 2) . Although all four cases with positive detection of the virus genome in skin tissue were included in group A, detection of HHV-6 genome in skin tissues was not significantly different between the two groups. HHV-6 viremia was found in nine of 15 (60%) cases in group A, compared with none of 10 (0%) cases in Table 2 Association between the results of virological examinations and the onset of skin rash b If HHV-6 DNA was detected in the skin tissue and/or the virus was isolated from PBMCs between 10 days before or after the onset of skin rash, we defined it as HHV-6 infection.
group B. This difference was statistically significant (P = 0.008). Moreover, HHV-6 infection (as determined by positive detection of skin rash-related viremia or the presence of the virus genome in skin tissue) was demonstrated in 11 of 15 (73.3%) cases in group A, compared with none of 10 (0%) cases in group B (P = 0.001).
Discussion
The HHV-6 genome was detected in skin tissue in four cases and two of those cases had HHV-6 viremia at the time of skin biopsy. Le Cleach et al 8 reported one recipient with active HHV-6 infection (positive detection by plasma PCR) concurrent with the presence of the virus genome in skin tissue. These results suggest that HHV-6 can reach skin tissue during viremia, and that the virus might play an important role in developing skin rash. However, it is not clear whether active virus replication occurs at the site of skin lesions. Although they were not able to identify the virus antigen in skin tissues by immunohistochemical analysis, it is important to continue to perform histological analyses, including in situ hybridization, to elucidate the localization of the virus in skin tissues. In our study, HHV-6 genome was detected in the skin tissue in another two cases (cases 12 and 13), although HHV-6 was not isolated from their PBMC at the same time. It is possible that we were not able to obtain an appropriate blood sample for virus isolation and more frequent blood sampling may be needed to overcome this.
HHV-6 infection and the onset of skin rash occurred simultaneously in seven (cases 5, 10, 11, 12, 13, 14 and 15) of 11 cases with the virus infection (as determined by positive detection of skin rash-related viremia or the presence of the virus genome in skin tissue). It is likely that HHV-6 is a trigger for acute GVHD as suggested by Appleton et al. 7 Although they did not monitor active HHV-6 infection in their study, they found a significant linear trend between detection of HHV-6 genome in biopsy tissue obtained prior to or concomitant with the onset of GVHD. Since the HHV-6 genome was detected in skin tissue obtained from four of the seven cases, it is possible that a skin rash might be a viral exanthem caused by active HHV-6 infection. It is difficult to diagnose a skin rash, starting around 2 weeks after BMT, as acute GVHD, even if histological examination is carried out. Thus, further study is necessary to discriminate between acute GVHD exacerbated by HHV-6 infection and viral exanthem.
HHV-6 was isolated 5 to 10 days after the onset of skin rash in four cases (cases 6, 7, 8 and 9). It appears that HHV-6 reactivation was induced by acute GVHD and/or treatment in these cases. Thus, together with present data and the results of previous studies, it is considered that there are three different pathological mechanisms for developing acute GVHD or skin rash after allogeneic BMT. One is the viral exanthem caused by HHV-6 infection, the second is HHV-6 acting as a trigger for acute GVHD, and the third is acute GVHD inducing HHV-6 reactivation. If HHV-6 is a trigger for acute GVHD or skin rash, anti-viral drugs should be administered to the recipients, or prophylactic anti-viral treatment may be effective for preventing acute GVHD or skin rash resembling acute GVHD. Alternatively, if HHV-6 reactivation is induced by acute GVHD, anti-GVHD treatment is more important than anti-viral treatment for controlling the clinical symptoms.
Although there are several studies suggesting a positive association between HHV-6 and acute GVHD or skin rash, little is known about the timing of HHV-6-related acute GVHD or skin rash. As in previously reported studies, 4, 5 HHV-6 was isolated in the early post-transplantation period in this study. Moreover, skin rash-related viremia and HHV-6 infection occurred more frequently in group A than in group B (P = 0.008 and 0.001, respectively). These results indicate that HHV-6 plays an important role in causing skin rash or acute GVHD, appearing within 30 days after transplantation. Furthermore, it seems that a skin rash appearing after 30 days post transplant is more likely to be GVHD related and not related to a viral infection. So in order to clarify the role of HHV-6 in the pathogenesis of skin rash or acute GVHD, our future studies are focusing on symptoms occurring within 30 days of BMT.
